Related Experiment Video
Updated: Jan 20, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
Ruth Röck1, Johanna E Mayrhofer1, Omar Torres-Quesada1
1Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Abstract:
Oncogenic BRAF mutations initiate tumor formation by unleashing the autoinhibited kinase conformation and promoting RAS-decoupled proliferative RAF-MEK-ERK signaling. We have engineered luciferase-based biosensors to systematically track full-length BRAF conformations and interactions affected by tumorigenic kinase mutations and GTP loading of RAS. Binding of structurally diverse αC-helix-OUT BRAF inhibitors (BRAFi) showed differences in specificity and efficacy by shifting patient mutation-containing BRAF reporters from the definitive opened to more closed conformations. Unexpectedly, BRAFi engagement with the catalytic pocket of V600E-mutated BRAF stabilized an intermediate and inactive kinase conformation that enhanced binary RAS:RAF interactions, also independently of RAF dimerization in melanoma cells. We present evidence that the interference with RAS interactions and nanoclustering antagonizes the sequential formation of drug-induced RAS:RAF tetramers. This suggests a previously unappreciated allosteric effect of anticancer drug-driven intramolecular communication between the kinase and RAS-binding domains of mutated BRAF, which may further promote paradoxical kinase activation and drug resistance mechanisms.
Insights
Oncogenic BRAF mutations drive cancer by altering RAF signaling. BRAF inhibitors unexpectedly stabilize inactive conformations, enhancing RAS interactions and potentially promoting drug resistance.
Area of Science:
- Molecular biology
- Cancer research
- Biochemistry
Background:
- Oncogenic BRAF mutations are key drivers of tumor formation.
- These mutations activate the RAF-MEK-ERK signaling pathway, promoting cell proliferation.
- Understanding BRAF conformational changes and interactions is crucial for targeted therapy.
Purpose of the Study:
- To systematically track full-length BRAF conformations and interactions.
- To investigate the effects of tumorigenic mutations and RAS GTP loading on BRAF.
- To analyze the specificity and efficacy of BRAF inhibitors (BRAFi).
Main Methods:
- Engineered luciferase-based biosensors to monitor BRAF.
- Studied BRAF conformation shifts upon BRAFi binding.
- Investigated RAS:RAF interactions and nanoclustering in melanoma cells.
Main Results:
- Structurally diverse BRAFi shifted BRAF reporters between open and closed conformations.
- BRAFi binding to V600E-mutated BRAF stabilized an inactive conformation.
- This stabilization enhanced binary RAS:RAF interactions, independent of RAF dimerization.
Conclusions:
- BRAFi can induce previously unappreciated allosteric effects on mutated BRAF.
- Interference with RAS interactions antagonizes drug-induced RAS:RAF tetramer formation.
- These findings suggest mechanisms for paradoxical kinase activation and drug resistance.
Related Concept Videos
Conformity
The Ras Gene
Ras is a...
Binary Fission
Binary Fission
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

